Steven M Rowe Selected Research

lumacaftor

1/2022	Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.
1/2022	Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.
1/2021	Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
1/2021	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
1/2020	Novel Therapy of Bicarbonate, Glutathione, and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport.
2/2017	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
1/2017	A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis.
1/2015	Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
7/2014	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
1/2012	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven M Rowe Research Topics

Disease

104	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 12/2006
18	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 10/2010
15	Inflammation (Inflammations) 11/2022 - 04/2008
11	Lung Diseases (Lung Disease) 11/2021 - 04/2008
10	Chronic Bronchitis 01/2022 - 02/2014
7	Rhinosinusitis 01/2022 - 09/2011
7	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 01/2009
5	Infections 01/2022 - 07/2014
4	Dehydration (Water Stress) 01/2022 - 11/2018
3	Sinusitis 01/2022 - 01/2020
3	Dyspnea (Shortness of Breath) 01/2021 - 02/2014
3	Fibrosis (Cirrhosis) 01/2020 - 11/2018
3	Diarrhea 07/2019 - 03/2014
3	Emphysema 11/2018 - 08/2015
2	Cough 01/2022 - 01/2016
2	Bronchitis 01/2022 - 01/2017
2	Headache (Headaches) 11/2021 - 01/2021
2	Airway Obstruction (Choking) 10/2019 - 01/2016
2	Pancreatitis 07/2019 - 12/2013
2	Weight Gain 01/2019 - 03/2017
2	Lung Injury 11/2018 - 02/2014
2	Hypoxia (Hypoxemia) 01/2017 - 10/2013
1	COVID-19 01/2022
1	Hypertrophy 01/2022
1	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2022
1	Respiratory Insufficiency (Respiratory Failure) 02/2021
1	Respiratory Sounds (Crackle) 01/2021
1	Bronchial Spasm 01/2021
1	Nausea 01/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Fatigue 01/2021
1	Synucleinopathies 01/2020
1	Persistent Infection 01/2020
1	Chronic Disease (Chronic Diseases) 01/2020
1	Parkinson Disease (Parkinson's Disease) 01/2020

Drug/Important Bio-Agent (IBA)

48	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2022 - 12/2006
34	ivacaftorIBA 11/2022 - 11/2010
26	ChloridesIBA 01/2022 - 09/2011
15	SmokeIBA 01/2022 - 10/2010
12	Proteins (Proteins, Gene)FDA Link 11/2022 - 04/2008
11	Nonsense Codon (Nonsense Mutation)IBA 01/2021 - 07/2007
10	lumacaftorIBA 01/2022 - 01/2012
9	ivacaftor drug combination tezacaftorIBA 01/2022 - 11/2017
9	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2007
8	Pharmaceutical PreparationsIBA 01/2022 - 01/2009
6	elexacaftorIBA 01/2022 - 10/2018
5	Bicarbonates (Hydrogen Carbonate)IBA 01/2020 - 10/2013
4	Expectorants (Mucolytics)IBA 01/2022 - 12/2018
4	atalurenIBA 01/2020 - 01/2009
4	MucinsIBA 01/2020 - 12/2018
4	AnionsIBA 04/2019 - 07/2013
4	Ion Channels (Ion Channel)IBA 12/2018 - 01/2012
4	AminoglycosidesIBA 11/2011 - 07/2007
3	Epithelial Sodium ChannelsIBA 01/2022 - 10/2018
3	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 11/2010
3	EnzymesIBA 01/2020 - 07/2019
2	acebilustatIBA 11/2021 - 01/2018
2	Chloride Channels (Chloride Channel)IBA 01/2021 - 07/2019
2	icenticaftorIBA 01/2021 - 01/2020
2	Antisense OligonucleotidesIBA 01/2021 - 01/2019
2	Terminator Codon (Termination Codon)IBA 01/2021 - 01/2009
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 12/2006
2	Glutathione (Reduced Glutathione)IBA 01/2020 - 09/2007
2	tezacaftorIBA 11/2019 - 11/2017
2	CollagenIBA 11/2018 - 04/2008
2	Heme (Haem)IBA 11/2018 - 08/2015
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018 - 10/2017
2	Interleukin-8 (Interleukin 8)IBA 10/2017 - 06/2015
2	RoflumilastIBA 01/2017 - 03/2014
2	Phosphodiesterase 4 InhibitorsIBA 01/2017 - 03/2014
2	SodiumIBA 01/2017 - 07/2013
2	Adrenergic Agents (Adrenergic Drugs)IBA 07/2014 - 02/2014
2	Tobramycin (Nebcin)FDA LinkGeneric 07/2014 - 09/2007
2	HMGB1 Protein (HMG1)IBA 03/2010 - 10/2008
1	ProteomeIBA 11/2022
1	Aligeron (AS 2)IBA 01/2022
1	Glucosamine (Dona)IBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Pregnancy-Associated alpha 2-Macroglobulins (alpha 2 Macroglobulin)IBA 01/2022
1	riociguatIBA 11/2021
1	leukotriene A4 hydrolaseIBA 11/2021
1	Hyaluronic Acid (Hyaluronan)IBA 02/2021
1	ColforsinIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Adenosine Triphosphate (ATP)IBA 11/2020
1	Protein AggregatesIBA 01/2020
1	p300-CBP-associated factorIBA 01/2020
1	NADPH Oxidase 4IBA 01/2020
1	Acetates (Acetic Acid Esters)FDA Link 01/2020
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2020
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2020
1	Volatile Fatty AcidsIBA 01/2020

Therapy/Procedure

27	Therapeutics 01/2022 - 12/2006
2	Aftercare (After-Treatment) 03/2017 - 03/2015
1	Mechanical Ventilators (Ventilator) 02/2021
1	Noninvasive Ventilation 02/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	High-Protein Diet 01/2020
1	Stents 01/2020